1. Acknowledgement

   Announcement 17 September 2012 Pages: 1183 - 1185

2. Comment on “The economics of follow-on drug research and development: Trends in entry rates and the timing of development”

   • Aidan Hollis

   Commentary 17 September 2012 Pages: 1187 - 1192

3. The economics of follow-on drug research and development: Trends in entry rates and the timing of development — The authors’ reply

   • Joseph A. DiMasi
   • Cherie Paquette

   Commentary 17 September 2012 Pages: 1193 - 1202

4. No room for kinkiness in a public healthcare system

   • Jack Dowie

   Commentary 17 September 2012 Pages: 1203 - 1205

5. Cost-effectiveness acceptability curves and a reluctance to lose

   • Johan L. Severens
   • Daniëlle E. M. Brunenberg
   • Manuela A. Joore

   Leading Article 17 September 2012 Pages: 1207 - 1214

   

6. Willingness to pay for inhaled insulin

   • Hamid Sadri
   • Linda D. MacKeigan
   • Thomas R. Einarson

   Original Research Article 17 September 2012 Pages: 1215 - 1227

   

7. Estimating mean total costs in the presence of censoring

   • Tracey A. Young

   Original Research Article 17 September 2012 Pages: 1229 - 1242

   

8. A willingness-to-pay assessment of parents’ preference for shorter duration treatment of acute otitis media in children

   • Delphine Gueylard Chenevier
   • Jacques LeLorier

   Original Research Article 17 September 2012 Pages: 1243 - 1255

   

9. Pramipexole and levodopa in early parkinson’s disease

   • Katia Noyes
   • Andrew W. Dick
   • Robert G. Holloway

   Original Research Article 17 September 2012 Pages: 1257 - 1270

   

10. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer’s disease

    • Colin Green
    • Joanna Picot
    • Andrew Clegg

    Original Research Article 17 September 2012 Pages: 1271 - 1282

    

11. Rizatriptan

    • Paul L. McCormack
    • Rachel H. Foster

    Adis Pharmacoeconomic Drug Evaluation 17 September 2012 Pages: 1283 - 1298